André-Guy Martin
Chercheur associé
Axe Oncologie
Publications
Voir tout-
article Fabi F, Crook J, Jolicoeur M, Rauth S, Koll W, Tisseveransinghe S, Ebacher A, Niazi T, Duplan D, Bernard AA, Vavassis P, Foster W, Vigneault É and Archambault L, Beaulieu L, Lavallée MC, Lacroix F, Carignan D, Martin AG
Pelvic nodes ultra-hypo fractionated versus conventionally fractionated IMRT with HDR brachytherapy in prostate cancer: interim analysis of a collaborative multi-institutional no…
Radiother Oncol 221 2026.
-
article Dionne P, Martin AG, Ouellet É and Roy JC, Sidibé I, Froment MA, Vigneault É and Foster W, Bachand F, Archambault L, Poulin É
Assessing inter-observer variability in prostate and GTV segmentation on mpMRI: A comparison between radiation oncologists and AI-based method
J Appl Clin Med Phys 27 (4), 2026.
-
article Martínez C, Tisseverasinghe S, Karim MU, Ka K, Nabid A, Kaldany E, Bettahar R, Vincent L, Martin AG, Jolicoeur M, Yassa M, Barkati M, Bahoric B, Archambault R, Villeneuve H, Mohiuddin M, Niazi T
Conventional vs. hypofractionated radiotherapy for high-risk prostate cancer (PCS5), randomized, non-inferiority, phase III trial: Post hoc analysis of radiation therapy toxiciti…
Radiother Oncol 219 2026.
Projets
- Two Fractions Study of Hypofractionated Ablative Radiotherapy for Prostate Cancer (2SHARP), du 2025-03-14 au 2027-03-13
- Création de la base de données intégrée PRECISE-LDR (PRostatE Cancer Integrated data SEt-LDR), du 2025-04-01 au 2028-04-01
- UH3: Three Ultra Hypofractionated IGRT fractions + brachytherapy boost for localised Prostate cancer, du 2026-07-15 au 2027-03-31
- 2SHARP:Two Fractions Study of Hypofractionated Ablative Radiotherapy for Prostate Cancer. , du 2024-06-19 au 2025-03-31
- Création d’un outil d’intelligence artificielle visant la prédiction des toxicités des patients traités par radiothérapie en contexte de cancers de la prostate (PROstate Toxicity Evaluation and Control Through AI – PROTECTA-LDR)., du 2025-06-24 au 2026-03-31